Esperion Therapeutics was initially published as one of our 7investing Community's New Ideas in December 2024

Discuss Esperion Therapeutics in our Community Forum

Background

The following comes directly from our initial Community recommendation. 7investing's opinions may differ from the person(s) who submitted this community research.

Esperion sells a drug that is a Statin alternative where it either doesn’t have the desired effect or can not be tolerated.

Esperion holds rights in the US market which sales have been growing over 50% and licenses out the rights in Europe and Japan.

The Japan partner has just filed a NDA to the Japan ministry of health which should trigger a 20M milestone payment to Esperion.